Alfred Gugerell1,2, Dirk Sorgenfrey3, Maria Laggner1, Jürgen Raimann4, Anja Peterbauer5, Daniel Bormann1, Susanne Suessner5, Christian Gabriel6, Bernhard Moser1, Tobias Ostler7, Michael Mildner8, Hendrik J Ankersmit1,9,10. 1. Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria. 2. Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. 3. Dr. Regenold GmbH, Badenweiler, Germany. 4. Charles River Laboratories Germany GmbH (CRL), Cologne, Germany. 5. Red Cross Blood Transfusion Service of Upper Austria, Linz, Austria. 6. Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria. 7. SYNLAB Analytics and Services Switzerland AG, Birsfelden, Switzerland. 8. Research Division of Biology and Pathobiology of the Skin, Department of Dermatology, Medical University of Vienna, Vienna, Austria. 9. Wiener Wirtschaftsagentur Project 2343727 "APOSEC to clinic", Medical University Vienna, Vienna, Austria. 10. Austrian Research Promotion Agency FFG Projects 852748 and 862068 "APOSEC", Medical University Vienna, Vienna, Austria.
Abstract
BACKGROUND: Viral reduction and inactivation of cell-derived biologicals is paramount for patients' safety and so viral reduction needs to be demonstrated to regulatory bodies in order to obtain marketing authorisation. Allogeneic human blood-derived biological medicinal products require special attention. APOSECTM, the secretome harvested from selected human blood cells, is a new biological with promising regenerative capabilities. We evaluated the effectiveness of inactivation of model viruses by methylene blue/light treatment, lyophilisation, and gamma irradiation during the manufacturing process of APOSECTM. MATERIALS AND METHODS: Samples of intermediates of APOSECTM were acquired during the manufacturing process and spiked with bovine viral diarrhoea virus (BVDV), human immunodeficiency virus type 1 (HIV-1), pseudorabies virus (PRV), hepatitis A virus (HAV), and porcine parvovirus (PPV). Viral titres were assessed with suitable cell lines. RESULTS: Methylene blue-assisted viral reduction is mainly effective against enveloped viruses: the minimum log10 reduction factors for BVDV, HIV-1, and PRV were ≥6.42, ≥6.88, and ≥6.18, respectively, with no observed residual infectivity. Viral titres of both HAV and PPV were not significantly reduced, indicating minor inactivation of non-enveloped viruses. Lyophilisation had minor effects on the viability of several enveloped model viruses. Gamma irradiation contributes to the viral safety by reduction of enveloped viruses (BVDV: ≥2.42; HIV-1: 4.53; PRV: ≥4.61) and to some degree of non-enveloped viruses as seen for HAV with a minimum log10 reduction factor of 2.92. No significant reduction could be measured for the non-enveloped virus PPV (2.60). DISCUSSION: Three manufacturing steps of APOSECTM were evaluated under Good Laboratory Practice conditions for their efficacy at reducing and inactivating potentially present viruses. It could be demonstrated that all three steps contribute to the viral safety of APOSECTM.
BACKGROUND: Viral reduction and inactivation of cell-derived biologicals is paramount for patients' safety and so viral reduction needs to be demonstrated to regulatory bodies in order to obtain marketing authorisation. Allogeneic human blood-derived biological medicinal products require special attention. APOSECTM, the secretome harvested from selected human blood cells, is a new biological with promising regenerative capabilities. We evaluated the effectiveness of inactivation of model viruses by methylene blue/light treatment, lyophilisation, and gamma irradiation during the manufacturing process of APOSECTM. MATERIALS AND METHODS: Samples of intermediates of APOSECTM were acquired during the manufacturing process and spiked with bovineviral diarrhoea virus (BVDV), humanimmunodeficiency virus type 1 (HIV-1), pseudorabies virus (PRV), hepatitis A virus (HAV), and porcine parvovirus (PPV). Viral titres were assessed with suitable cell lines. RESULTS:Methylene blue-assisted viral reduction is mainly effective against enveloped viruses: the minimum log10 reduction factors for BVDV, HIV-1, and PRV were ≥6.42, ≥6.88, and ≥6.18, respectively, with no observed residual infectivity. Viral titres of both HAV and PPV were not significantly reduced, indicating minor inactivation of non-enveloped viruses. Lyophilisation had minor effects on the viability of several enveloped model viruses. Gamma irradiation contributes to the viral safety by reduction of enveloped viruses (BVDV: ≥2.42; HIV-1: 4.53; PRV: ≥4.61) and to some degree of non-enveloped viruses as seen for HAV with a minimum log10 reduction factor of 2.92. No significant reduction could be measured for the non-enveloped virus PPV (2.60). DISCUSSION: Three manufacturing steps of APOSECTM were evaluated under Good Laboratory Practice conditions for their efficacy at reducing and inactivating potentially present viruses. It could be demonstrated that all three steps contribute to the viral safety of APOSECTM.
Authors: H J Ankersmit; K Hoetzenecker; W Dietl; A Soleiman; R Horvat; M Wolfsberger; C Gerner; S Hacker; M Mildner; B Moser; M Lichtenauer; B K Podesser Journal: Eur J Clin Invest Date: 2009-04-16 Impact factor: 4.686
Authors: Konrad Hoetzenecker; Matthias Zimmermann; Wolfram Hoetzenecker; Thomas Schweiger; Dagmar Kollmann; Michael Mildner; Balazs Hegedus; Andreas Mitterbauer; Stefan Hacker; Peter Birner; Christian Gabriel; Mariann Gyöngyösi; Przemyslaw Blyszczuk; Urs Eriksson; Hendrik Jan Ankersmit Journal: Eur Heart J Date: 2013-01-14 Impact factor: 29.983
Authors: Lucian Beer; Matthias Zimmermann; Andreas Mitterbauer; Adolf Ellinger; Florian Gruber; Marie-Sophie Narzt; Maria Zellner; Mariann Gyöngyösi; Sibylle Madlener; Elisabeth Simader; Christian Gabriel; Michael Mildner; Hendrik Jan Ankersmit Journal: Sci Rep Date: 2015-11-16 Impact factor: 4.379
Authors: Mohammad Mahdi Kasiri; Lucian Beer; Lucas Nemec; Florian Gruber; Sabine Pietkiewicz; Thomas Haider; Elisabeth Maria Simader; Denise Traxler; Thomas Schweiger; Stefan Janik; Shahrokh Taghavi; Christian Gabriel; Michael Mildner; Hendrik Jan Ankersmit Journal: Eur J Clin Invest Date: 2016-09-26 Impact factor: 4.686
Authors: Elisabeth Simader; Lucian Beer; Maria Laggner; Vera Vorstandlechner; Alfred Gugerell; Michael Erb; Polina Kalinina; Dragan Copic; Doris Moser; Andreas Spittler; Erwin Tschachler; Hendrik Jan Ankersmit; Michael Mildner Journal: Cell Death Dis Date: 2019-09-30 Impact factor: 8.469
Authors: Alfred Gugerell; Ghazaleh Gouya-Lechner; Helmut Hofbauer; Maria Laggner; Franz Trautinger; Gabriele Almer; Anja Peterbauer-Scherb; Marcus Seibold; Wolfram Hoetzenecker; Christiane Dreschl; Michael Mildner; Hendrik Jan Ankersmit Journal: Trials Date: 2021-01-06 Impact factor: 2.279